Interstitial lung disease and the STING pathway

Area of Science:

• Immunology
• Genetics
• Pulmonology

Background:

• Ultrarare monogenic conditions, STING-associated vasculopathy with onset in infancy (SAVI) and coatomer protein complex subunit alpha (COPA) syndrome, are linked to interstitial lung disease (ILD).
• Genetic mutations in these conditions highlight the role of the stimulator of interferon genes (STING) immune pathway in ILD pathogenesis.
• The therapeutic potential of STING-focused treatments for SAVI and COPA syndrome is being explored, but its relevance to common ILDs remains unclear.

Purpose of the Study:

• To provide an overview of SAVI and COPA syndrome, including the nature of ILD associated with these conditions.
• To review current evidence on STING activity in the pathogenesis of ILD in SAVI and COPA syndrome.
• To explore the potential role of STING in more common forms of ILD by discussing data from various ILDs and model systems.

Main Methods:

• Literature review of genetic mutations underlying SAVI and COPA syndrome.
• Analysis of existing studies on STING pathway activity in rare and common ILDs.
• Examination of data from various ILD models and systems.

Main Results:

• Identification of genetic mutations implicating the STING pathway in SAVI and COPA syndrome-related ILD.
• Evidence suggests a role for STING in the pathogenesis of ILD in these ultrarare conditions.
• The relevance of STING to common ILDs requires further investigation.

Conclusions:

• The STING immune pathway plays a significant role in the pathogenesis of ILD in SAVI and COPA syndrome.
• STING-focused therapeutics represent a potential treatment avenue for SAVI and COPA syndrome.
• Further research is warranted to elucidate the role of STING in the pathogenesis of more common forms of ILD.